Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) : Predictive Marker and Mechanism

NCT02803515TerminatedNAINTERVENTIONAL

Summary

Peritoneal carcinomatosis (PC) is the stage III of the FIGO ovarian cancer staging. It corresponds to an advanced stage with a relative 5 year survival rate of 52%. The multimodal treatment approach combines neoadjuvant chemotherapy, cytoreductive surgery of macroscopic lesions, and hyperthermic intraperitoneal chemotherapy (HIPEC). It has significantly improved survival rate in patients with ovarian PC and decreased recurrence and mortality rate by 21%. The efficacy of HIPEC is based on chemotherapy potentiated by the hyperthermia (43°). However, the cellular mechanisms involved are not fully understood, but they include cell death pathways and heat shock proteins (Hsp70 and Hsp90). RICCI et al. showed, based on pre-clinical models, that the efficacy of HIPEC was partly due to the overexpression and exposure of HSP90 on the cell surface leaded to an anti-cancer immune response. The aims of this study are to validate these findings in tissue samples of patients with ovarian PC. We will constitute a bank of isolated tumor samples before and after HIPEC and measure postoperative HSP90 serum levels in order to establish if they are predictive of a response. HSPs expression on the cancer cell surface will be determined by flow cytometry. Forty-four patients will be included. Elucidating the underlying mechanisms of HIPEC will broaden therapeutic possibilities including the use of new immunotherapy. The multimodal approach could improve the efficacy of HIPEC with a minimal systemic toxicity.

Key Facts

Lead Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

Start Date

2017-01-16

Completion Date

2017-07-02

Study Type

INTERVENTIONAL

Official Title

HSP90 as a Predictive Marker of the Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Carcinomatosis From Ovarian Origin.

Interventions

peripheral venous blood samples

Conditions

Peritoneal Carcinomatosis

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* Females over 18 years.
* Indication of Hyperthermic Intra Peritoneal Chemotherapy (HIPEC) for peritoneal carcinomatosis from ovarian origin
* Obtaining written informed consent and signed for participation in the study and conservation of samples taken.
* Affiliation to a social security scheme.

Non-inclusion criteria

* Major patients protected by law or deprived of liberty.
* Patients pregnant women in labor or breastfeeding.
* Refusal of participation
* Another cause of peritoneal carcinomatosis

Exclusion Criteria:

* consent withdrawn

Outcome Measures

Primary Outcomes

Changes in serum levels of HSP90 and 70 on peripheral venous samples.

Changes in serum levels of HSP90 and 70 postoperatively HIPEC (Day 1, day 3 and day 5 postoperative) compared to basal levels measured preoperatively on peripheral venous samples. Patients who had HIPEC will be compared with patients overturned on early intervention

Time frame: basal levels (preoperatively), postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)

Locations

Digestive department - Archet hospital, Nice, France